CD44 is the main cellular receptor for hyaluronic acid (HA). We previously found that overexpression of CD44 inhibited tumor growth of mouse fibrosarcoma cells in mice. Here, we show that soluble recombinant CD44 HAbinding domain (CD44-HABD) acts directly onto endothelial cells by inhibiting endothelial cell proliferation in a cell-specific manner. Consequently, soluble recombinant CD44-HABD also blocked angiogenesis in vivo in chick and mouse, and thereby inhibited tumor growth of various origins at very low doses (0.25 mg/kg Â day). The antiangiogenic effect of CD44 is independent of its HAbinding capacity, since mutants deficient in HA binding still maintain their antiangiogenic and antiproliferative properties. Recombinant CD44-HABD represents a novel class of angiogenesis inhibitors based on a cell-surface receptor.
Introduction
CD44 is a transmembrane receptor for hyaluronic acid (HA) (Aruffo et al., 1990) that is functional in HA metabolism (Culty et al., 1992; Kaya et al., 1997) , cell migration (Thomas et al., 1992) and cell adhesion (Lesley et al., 1993) . The highly conserved link module located in the amino-terminal portion of the extracellular domain mediates CD44 binding to HA. CD44 displays a complex pattern of alternative splicing within its extracellular domain, and the genomic structure of the CD44 gene reveals the presence of 10 alternatively spliced exons (Screaton et al., 1992) . Alternatively spliced CD44 variant isoforms have been reported to confer a metastatic phenotype to tumor cells (Gunthert et al., 1991; Arch et al., 1992) . We previously found that the CD44 standard isoform induced metastatic capacity of mouse fibrosarcoma cells while it inhibited subcutaneous tumor growth in mice (Kogerman et al., 1997) . Mouse fibrosarcoma cells overexpressing the human CD44 standard isoform showed prolonged latency time for growth in mice compared to parental cells, and the transgene CD44 expression was downregulated once subcutaneous tumors were established. Moreover, tumorigenicity studies with SV40 large T-transformed CD44-negative fibroblasts showed that reintroduction of the CD44 standard isoform into these cells significantly reduced subcutaneous tumor growth in mice (Schmits et al., 1997) .
The formation of solid tumors is dependent on the formation of new blood vessels by angiogenesis . A switch to an angiogenic phenotype is one of the critical steps in the development of a malignant tumor phenotype and is dependent on the balance between pro-and anti-angiogenic factors in the tumor microenvironment. Several endogenous angiogenesis inhibitors have been described, including endostatin (a fragment of collagen type XVIII) (O'Reilly et al., 1997) , angiostatin (a fragment of plasminogen) (O'Reilly et al., 1994) , thrombospondin (Guo et al., 1997) , antithrombin (O'Reilly et al., 1999) , and pigment epithelium-derived factor (Stellmach et al., 2001) . There are two types of angiogenesis inhibitors: direct inhibitors acting directly onto vascular cells and indirect inhibitors acting on neighboring cells or factors in the surrounding that would otherwise stimulate angiogenesis (Kerbel and Folkman, 2002) .
CD44 has been suggested to promote tumor angiogenesis and growth by mediating localization of matrix metalloprotease-9 (MMP-9) to the tumor cell surface Stamenkovic, 1999, 2000) , since overexpression in tumor cells of a naturally occurring soluble CD44 isoform disrupted the localization of MMP-9 to the tumor cell surface and inhibited tumor growth and invasion Stamenkovic, 1999, 2000) . The resulting tumors were also less vascularized, suggesting that the tumor growth inhibition might be related to an inhibition of tumor angiogenesis Stamenkovic, 1999, 2000) .
Given that CD44 overexpression on the tumor cell surface can inhibit tumor growth, we hypothesized that a purified recombinant CD44-HABD might serve as an angiogenesis inhibitor and may thereby block tumor growth. Furthermore, as CD44 is the main cellular receptor for HA, we wanted to test whether the potential effects on angiogenesis and tumor growth could be dependent on the HA-binding properties of CD44. Therefore, we produced recombinant CD44-HABD and various non-HA-binding mutants thereof and tested them in various models of cell proliferation, angiogenesis and tumor growth.
We report here that soluble CD44-HABD inhibits tumor growth and angiogenesis. The observed tumor growth-and angiogenesis-inhibiting effect of CD44-HABD is independent of HA binding since a non-HAbinding mutant was equally effective. Furthermore, CD44-HABD blocked cell proliferation in an endothelial cell-specific manner and showed no effect on proliferation of tumor cells or untransformed epithelial or fibroblast cells. Therefore, recombinant CD44-HABD represents a new type of direct angiogenesis inhibitor based on a cell surface receptor.
Results
Recombinant CD44-HABD binds to HA and inhibits HA-induced endothelial cell migration
The HA-binding domain is the most evolutionary conserved region in the extracellular part of the CD44 receptor, with human and avian CD44 showing a 78% amino acid (aa) similarity and a 57% amino acid (aa) identity within aa 21-133 ( Figure 1a ). To test if CD44-HABD might inhibit tumor growth and angiogenesis, we created recombinant bacterial glutathione S-transferase (GST) fusion proteins of CD44-HABD (GST-HABD). We also generated three mutants of human CD44-HABD GST-fusion proteins at positions that have previously been demonstrated or predicted to make CD44 defective in HA binding (Bajorath et al., 1998) :
GST-HABD
R41A
(GST-R41A), GST-HABD R78SY79S (GST-R78SY79S), and the triple mutant GST-HABD R41AR78SY79S (GST-3MUT) (the numbers correspond to aa positions in full-length human CD44). To test the HA-binding capacity of the recombinant GST-HABD proteins, we performed a modified ELISA assay with immobilized HA. In this assay, wild-type CD44 fusion proteins were bound to HA in a concentration-dependent manner while the mutant protein did not display any binding significantly higher than the background even at high concentrations ( Figure 1b) . Given that CD44 mediates cell migration on HA (Thomas et al., 1992) , we then tested the effect of soluble CD44-HABD proteins on cell migration. We found that wild-type GST-HABD but not the GST-R41A non-HA-binding mutant inhibited HA-induced human aortic endothelial cell (HAEC) migration (Figure 1c ). This effect on cell migration was specific for HA-mediated migration, since migration towards collagen type I was not inhibited (data not shown). Furthermore, preincubation of endothelial cells with an antibody that specifically blocks CD44 binding to HA (GKW.A3; (Guo et al., 1994) ) also inhibited their migration towards HA (Figure 1c ). This demonstrates that while wild-type CD44-HABD binds to HA and inhibits HAinduced cell migration, all the mutants were deficient in these capacities. Figure 1 Properties of recombinant CD44-HABD. (a) Amino acid alignment of human and chick CD44-HABD demonstrates a high degree of sequence conservation during evolution; identical aa residues are shown in the middle and conservative replacements are indicated ( þ ). Amino acid residues involved in HA-binding are indicated with asterisks and residues mutated in this study are boxed. (b) GST-HABD, but not GST-3MUT or GST control bound to immobilized HA in a modified ELISA assay. (c) GST-HABD inhibits HA-induced human aortic endothelial cell migration, whereas GST-R41A non-HA-binding mutant had no effect. GKW.A3, a monoclonal antibody to CD44 that blocks CD44 binding to HA, also blocks HAEC haptotaxis towards HA. Error bars in (b) and (c) indicate s.e.
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Recombinant CD44-HABD proteins inhibit angiogenesis in the chick chorio-allantoic membrane
To test the effect of CD44-HABD on angiogenesis, we used a chick chorio-allantoic membrane (CAM) angiogenesis assay (Brooks et al., 1999) . We induced angiogenesis in 10-day-old chick embryo CAMs by the use of filter discs saturated with 100 ng/ml VEGF, 1 mg/ ml bFGF or 200 ng/ml TGFa. Growth factor-saturated filter discs were then treated by daily topical addition of 10 mg of GST-HABD, GST-3MUT, GST or vehicle alone. After 3 days, we dissected the filter discs with the surrounding CAM and analysed for angiogenesis by quantifying the number of blood vessel branch points under the filter disc area. Angiogenesis was induced to a similar degree by all three growth factors (Figure 2) . Importantly, the angiogenic effects of VEGF, bFGF and TGFa were completely abolished by GST-HABD or GST-3MUT but not by GST or PBS treatment (Figure 2a-f ). In addition, treatment with a GST-HABD R41A gave a similar inhibition (data not shown). Therefore, recombinant CD44-HABD blocked angiogenesis that was induced by three distinct angiogenic factors, indicating that CD44-HABD may inhibit angiogenesis regardless of the route of induction. Furthermore, surprisingly, this inhibition of angiogenesis by recombinant CD44 was independent of HA binding since the non-HA-binding mutants were as effective in blocking angiogenesis as wild-type CD44-HABD.
CD44-HABD specifically blocks endothelial cell proliferation
Angiogenesis is a complex process involving cell proliferation, invasion and cell motility. CD44-mediated migration of endothelial cells towards HA is dependent on its HA-binding properties (Figure 1c ). To analyse if CD44-HABD could execute a direct effect on vascular endothelial cells, we tested if CD44-HABD could directly bind to endothelial cells. Therefore, we labeled GST-HABD, GST-3MUT or GST protein alone with Alexa488 fluorochrome and tested binding of these proteins to different endothelial and non-endothelial cell lines. Flow cytometry analysis showed that GST-HABD and GST-3MUT proteins but not GST protein bound to CPAE endothelial cells but not to COS-1 kidney fibroblasts (data not shown), suggesting that the CD44-HABD may bind directly to a putative receptor present on endothelial cells.
Therefore, we tested if recombinant CD44-HABD proteins might affect endothelial cell proliferation. To this end, HUVEC and CPAE endothelial cells, as well as various other primary and tumor cells were grown in the Figure 3 ). This suggests that cell growth inhibition by CD44-HABD is endothelial cell specific. However, we did not detect any increase in apoptosis within the treated cell populations (data not shown), indicating that the primary effect on endothelial cells may be on cell proliferation.
To test if the effect on the endothelial cells was dosedependent, we performed a dose-response analysis on CPAE cells using an MTT assay followed by spectrophotometric detection. As shown in Figure 4 , both WT (GST-HABD) and 3MUT (GST-3MUT) versions of CD44-HABD inhibited the proliferation of CPAE cells at concentrations starting from 0.5 to 1 mg/ml. At the highest concentration used (10 mg/ml), GST control protein also has a slight effect on cell proliferation but this effect was much weaker than that seen with CD44-HABD proteins. These data indicate that recombinant CD44-HABD proteins inhibit the proliferation of endothelial cells in a dose-dependent manner.
Recombinant CD44-HABD inhibits tumor growth and angiogenesis at low doses independent of HA binding Given that CD44-HABD inhibits both angiogenesis in the chick CAM and endothelial cell proliferation, we wanted to test if our recombinant proteins could also inhibit tumor growth. For this purpose, we injected 1 Â 10 6 BxPC-3 pancreatic human adenocarcinoma or SMMU-1 melanoma cells subcutaneously (s.c.) onto the backs of nude mice. When the tumors appeared as palpable nodules, mice received GST-HABD, GST-3MUT or GST by s.c. injections every second day into a region proximal to the tumor. BxPC-3 cells gave rise to slow-growing tumors. The GST-treated controls reached an average weight of 0.26770.042 g (n ¼ 6) on day 52 when the mice were killed (Figure 5a-c) . However, treatment of the mice with 0.25 mg/kg day GST-HABD or GST-3MUT protein significantly inhibited BxPC-3 tumor growth and reduced the average tumor weight by approximately 60% (0.10870.028 g; P ¼ 0.0159; n ¼ 6) and 70% (0.08570.017 g; P ¼ 0.0076; n ¼ 5), respectively ( Figure 5b ). We then performed the same experiment using the more aggressive SMMU-1 melanoma cell line and again observed a significant inhibition of tumor growth by approximately 50% by both GST-HABD and GST-3MUT treatment (average tumor weight after sacrifice after 16 days was 0.8170.061 g (P ¼ 0.0015; n ¼ 8) and 0.74670.132 g (P ¼ 0.0014; n ¼ 7), respectively), as compared to GSTtreated controls (1.55970.124 g; n ¼ 8) (Figure 6a-c) .
Next, we analysed mouse subcutaneous SMMU-1 and BxPC-3 tumors for blood vessel density by counting PECAM-1 (CD31)-positive blood vessels. GST-HABD or GST-3MUT treatment significantly reduced blood vessel density in SMMU-1 tumors compared to GST-control treatment (Figure 6d ), indicating that CD44-HABD as well as the GST-3MUT also blocked tumor-induced angiogenesis. Similar results were also obtained with BxPC-3 tumors (data not shown). Given that inhibition of angiogenesis is known to suppress tumor growth (Holmgren et al., 1995; O'Reilly et al., 1997 O'Reilly et al., , 1996 Parangi et al., 1996) , and that we found CD44-HABD to block angiogenesis directly (Figure 2) , 
Discussion
In this study, we describe a novel type of angiogenesis inhibitor, a domain of the cell surface receptor CD44 (CD44-HABD). CD44-HABD blocked angiogenesis in chick CAM induced by various growth factors. CD44-HABD acted directly on endothelial cells and blocked their cell proliferation, indicating that CD44-HABD may act as a direct angiogenesis inhibitor. Surprisingly, the inhibition of endothelial cell proliferation and angiogenesis by CD44-HABD was independent of HA binding, since CD44-HABD non-HA-binding mutant maintained the antiproliferative and antiangiogenic properties. Finally, treatment of mice with soluble CD44-HABD proteins significantly suppressed in vivo growth of different tumors and inhibited tumor vascularization. While inhibition of tumor angiogenesis by CD44-HABD is the most likely explanation for our results, alternative explanations cannot be excluded. For instance, CD44-HABD might prevent cell-cell contact of tumor cells precluding the development of a solid mass or it might alter the expression of stromal factors essential for tumor growth. Whatever the mechanism, the observed inhibition of tumor growth opens up the possibility that CD44-HABD may be developed into a drug for treatment of human cancer. Of course, much work remains to be carried out to test that possibility. As a first task, sufficient quantities of CD44 must be obtained to develop an intravenous injection protocol for this protein.
Recent reports show that CD44 extracellular domain can be released from the cell surface by proteolytic cleavage and incorporated into extracellular matrices (ECM) (Okamoto et al., 1999; Cichy et al., 2002; Okamoto et al., 2002) . Possible functions for soluble CD44 in ECM include organization of the matrix and the anchoring of growth factors to the ECM. Soluble CD44 levels are elevated in the blood during inflammation and CD44 proteolytic cleavage is enhanced in multiple tumors (Katoh et al., 1994; Okamoto et al., 2002) . In previous studies, disruption of tumor cell adhesion to HA by overexpression of soluble CD44 isoforms in tumor cells inhibited HA-induced melanoma cell proliferation and tumor growth in mice (Ahrens et al., 2001) . Furthermore, the metastatic capability of murine mammary carcinoma cells was inhibited by overexpression of CD44, these tumors could not be established in the secondary site and instead underwent apoptosis (Yu et al., 1997) . In both these cases, soluble CD44 acted by inhibiting binding of HA to cell surface CD44. The CD44 to HA interaction also plays a role in endothelial cell proliferation as antibodies against CD44 blocked a mitogenic response to HA in these cells (Lokeshwar et al., 1996; Trochon et al., 1996; Savani ) and CD44 expression was upregulated only in proliferating endothelial cells (Griffioen et al., 1997) .
In our experiments, however, inhibition of endothelial cell proliferation and angiogenesis by CD44-HABD was independent of HA binding, since CD44-HABD non-HA-binding mutants were equally effective in blocking endothelial cell proliferation. CD44-HABD bound to the cell surface of endothelial cells, suggesting that CD44-HABD may target a specific cell surface receptor. This receptor may be specific for endothelial cells or may interfere with a signaling pathway required specifically for endothelial cell proliferation. Naturally, identification of this putative receptor and its signaling mechanisms will be of great interest.
A number of CD44-binding proteins other than HA have been described, including HGF, bFGF, fibronectin, osteopontin, selectins, erbB2 and erbB3 (Jalkanen and Jalkanen, 1992; Bennett et al., 1995; Weber et al., 1996; van der Voort et al., 1999; Sherman et al., 2000; Dimitroff et al., 2001) . However, the binding of these proteins is dependent on various post-translational modifications of CD44 at alternative exons that are not present in our recombinant fusion proteins. The effects of endogenous CD44-HABD on angiogenesis and tumor growth might instead be caused by enzymes that are responsible for CD44 shedding. CD44-cleaving proteins belong to serine protease and metalloproteinase families; one enzyme that can digest CD44 is MT1-MMP (Kajita et al., 2001 ). However, MT1-MMP binds to the CD44 stem region and the CD44 HA-binding domain is not involved in this interaction (Mori et al., 2002) . Another interesting binding partner for CD44 is MMP-9; CD44 serves as a cell surface docking receptor for this protease (Yu and Stamenkovic, 1999) . MMP-9 is implicated in angiogenesis by releasing VEGF from extracellular matrix deposits during ECM proteolysis (Bergers et al., 2000) . A role for CD44 in angiogenesis has been suggested to be related to its capacity to bind MMP-9 (Yu and Stamenkovic, 2000) and the binding of MMP-9 to CD44 seems to be dependent on CD44 clustering by HA (Yu and Stamenkovic, 1999) . However, our preliminary results suggest that CD44-HAB-D R41AR78SY79S non-HA-binding mutant cannot bind MMP-9 (Pa¨ll et al., unpublished). Furthermore, the observed inhibition of endothelial cell proliferation by CD44-HABD might not be explained by blocking MMP-9 binding to CD44, since MMP-9 is affecting angiogenesis by ECM proteolysis (Bergers et al., 2000) , while no evidence is present for MMP-9-mediated direct effect on cell proliferation. Therefore, it is unlikely that the effects of CD44-HABD in angiogenesis are dependent on MMP-9 binding. An intriguing possibility is that CD44 HABD and its mutants may bind to other carbohydrates, for example, to sialyl Lewis X-containing saccharides implicated in angiogenesis. The structure of the CD44 link domain HA-binding surface corresponds closely to the Sialyl Lewis-X-binding site of Eselectin (Kohda et al., 1996; Bajorath et al., 1998) . The Sialyl Lewis-X-binding surface in E-selectin is smaller than the HA-binding surface in CD44. Mutations introduced into CD44 HABD to abolish HA binding may not overlap with putative binding site for Sialyl Lewis-X (Nguyen et al., 1993; Koch et al., 1995; Bajorath et al., 1998) . It will therefore be interesting to assess whether CD44 protein can bind to Sialyl Lewis-X or similar molecules and if this binding might be responsible for the observed inhibition of angiogenesis.
One possible explanation for the novel properties of recombinant CD44 proteins may be the lack of posttranslational modifications in our bacterially expressed proteins in contrast to proteins expressed in mammalian systems. CD44-HABD contains five putative N-linked glycosylation sites (Bartolazzi et al., 1996) . Therefore, we cannot exclude the possibility that novel binding site(s), masked by glycosylation in endogenous CD44, may become available in recombinant CD44-HABD and be responsible for the observed effects on angiogenesis. Taken together, our results suggest that HA-independent inhibition of endothelial cell proliferation by CD44-HABD is a novel mechanism for direct inhibition of angiogenesis. Therefore, new drugs based on CD44 sequences may be effective in treating human angiogenesis-dependent diseases such as cancer.
Materials and methods

Cell lines and cell culture
SMMU-1 melanoma cells (Guo et al., 1994) , normal human dermal fibroblasts (NHDF; Clonetics, San Diego, CA, USA), HEK-293 epithelial human embryonic kidney cells, MCF-7 human breast carcinoma cells, U373MG glioblastoma cells (ATCC, Manassas, VA, USA) were grown in DMEM with 10% FCS. Human pancreatic adenocarcinoma cells (BxPC-3; ATCC) were grown in RPMI 1640 with 10% FCS. Primary human umbilical vein endothelial cells (HUVEC) were grown in M199 with 20% FCS, 4 mM L-glutamine, 0.9 mg/ml heparin and 30 mg/ml endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY, USA). Cow pulmonary endothelial cells (CPAE; ATCC) were grown in MEM (25 mM HEPES) with 20% FCS, 2 mM L-glutamine and nonessential aa. Human aortic endothelial cells (HAEC) were obtained from Clonetics and grown according to the manufacturer's specifications.
Construction and purification of the human CD44-HABD as a GST fusion protein
Human CD44 standard isoform cDNA (Aruffo et al., 1990) was used to amplify the HA-binding domain, covering aa 21-132. The resulting PCR amplification product was cloned into a pGEX-KG vector (Guan and Dixon, 1991) . Generation of HABD non-HA-binding mutants was performed by means of the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Mutagenic oligo pairs R41A (5 0 -GAGAA AAATGGTGCCTACAGCATCTCTCGG-3 0 , 5 0 -AGATGCT GTAGGCACCATTTTTCTCCACG-3 0 ) and R78SY79S (5 0 -GACCTGCAGCTCTGGGTTCATAG-3 0 , 5 0 -ATGAACCCA GAGCTGCAGGTCTC-3 0 ) were used for introduction of R41A and/or R78SY79S mutations, respectively, into human CD44-HABD. Wild-type or mutant (R41A, R78SY79S or R41AR78SY79S) glutathione S-transferase CD44-HABD (GST-HABD) expression constructs were transformed into Escherichia coli BL21(DE3)pLysS strain. Protein expression was induced at 251C with 0.5 mM IPTG at OD 600 ¼ 0.7 for CD44 inhibits angiogenesis independently of HA binding T Päll et al 2.5 h and soluble recombinant proteins were purified using Glutathione Sepharose 4B beads (Amersham Biosciences AB, Uppsala, Sweden) according to the manufacturer's instructions.
Hyaluronic acid binding assay
High molecular weight HA at 1 mg/ml (Sigma) in PBS was used to coat Maxisorp (Nunc, Rochester, NY, USA) plates overnight at room temperature (RT). Wells were washed with PBS and blocked with 2% BSA for 2 h at RT. Purified proteins diluted in PBS were added to the wells and incubated for 1 h at RT. After three washes with PBS-0.1% Tween-20, the wells were incubated with mouse anti-GST antibody B-14 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at RT before further washing and 1 h incubation at RT with horseradish peroxidase-conjugated goat anti-mouse secondary antibody (Jackson Immunoresearch, West Grove, PA, USA). HA binding was visualized by OPD chromogenic substrate (Sigma) and the absorbance was measured spectrophotometrically at 450 nm.
Cell migration assay
Migration assays were performed in Transwell migration chambers (pore size 8 mm; Costar, London, UK) essentially as described (Zhang et al., 2002) . The lower compartment of the chambers contained 1 mg/ml high molecular weight HA (Sigma). Test proteins were added to the upper compartment at a final concentration of 10 mg/ml. For antibody inhibition assay, cells were preincubated for 30 min on ice with 10 mg/ml anti-CD44 mAb GKW.A3. Cells were added to the upper compartment of the Transwell chamber and allowed to migrate for 2 h. After the careful removal of all remaining cells in the upper chamber, the migrated cells were fixed and stained with 0.5% crystal violet. After washing, membranes were dried and bound dye was eluted with 10% acetic acid. The optical density of recovered eluate was read spectrophotometrically at 600 nm.
Tumor growth in mice and quantification of blood vessel density 1 Â 10 6 BxPC-3 or SMMU-1 cells were injected s.c. into the backs of 6-8-weeks-old female BALB/cABom nude mice (M&B, Ry, Denmark). When tumor nodules appeared, the mice started to receive subcutaneous injections proximal to the tumor of 20 mg (BxPC-3) or 50 mg (SMMU-1) of wild-type GST-HABD, GST-HABD R41AR78SY79S (GST-3MUT) or GST in 100 ml PBS. The treatment was repeated every second day. The tumor volume was measured and calculated using the formula (width 2 Â length) Â 0.52 (O'Reilly et al., 1997) . At the end of the experiments, the mice were killed and tumors were dissected and analysed for weight.
For immunohistochemical analysis, dissected tumors were fixed in 4% paraformaldehyde and embedded into paraffin. Tissue sections (5 mm-thick) were stained for blood vessels using goat anti-mouse PECAM-1 polyclonal antibody diluted 1:50 (M-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by incubation with biotin-conjugated rabbit anti-goat secondary antibody (Jackson Immunoresearch, West Grove, PA, USA). Antibody binding was detected using Vectastain ABC Kit and 3-amino-9-ethyl carbazole (AEC) as chromophore (Vector Laboratories, Burlingame, CA, USA). For quantification of blood vessel density three tumors per treatment were selected and 700-1600 of PECAM-1-positive blood vessels from each group were counted at Â 200 magnification.
Chick CAM angiogenesis assay
In all, 10-day-old chick embryos were prepared as described (Brooks et al., 1999) . For angiogenesis assay, filter discs, 5 mm in diameter, were saturated with 3 mg/ml cortisone acetate (Sigma), soaked with 100 ng/ml VEGF (Sigma), 1 mg/ml bFGF (Gibco Lifetech, Carlsbad, CA, USA) or 200 ng/ml TGFa (Sigma) in PBS and placed onto CAMs. Filter discs were then treated daily by topical addition of 10 mg of GST-HABD, GST-3MUT, GST in 25 ml PBS or vehicle alone. After 72 h, the filter discs and the surrounding CAM tissue were dissected and angiogenesis quantified in a dissection microscope. Angiogenesis was assessed in a double blind manner as the number of blood vessel branch points within the CAM area directly under the filter discs.
Cell cycle analysis
Exponentially growing cells were incubated for 48 h in the presence of 15 (CPAE) or 30 (all other cells) mg/ml GST-HABD, GST-3MUT or GST. All cells were incubated with proteins in serum containing medium with 10 mM HEPES pH 7.4. Tumor cells were incubated in 5% FCS while HUVEC and CPAE cells were grown in 10% FCS. After 48 h, cells were pulsed with 30 mg/ml bromodeoxyuridine (BrdU) for 60 min, harvested and fixed in ice-cold ethanol. Cells were then stained for BrdU with anti-BrdU mAb G3G4 (Developmental Studies Hybridoma Bank, University of Iowa, IA, USA) diluted 1:50 followed by a FITC-conjugated goat antimouse antibody (Jackson Immunoresearch, West Grove, PA, USA) in parallel staining with propidium iodide (PI). The cell cycle distribution was then analysed with a FACScan Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) after plotting FITC-content vs PI as previously described (Bakhiet et al., 2001) .
MTT cell proliferation assay
For the proliferation assay CPAE cells were plated onto 24-well culture plates (12,500 cells/well) and incubated overnight. Then complete media was replaced by 10% FCS-containing medium and the cells were incubated for 48 h in the presence of 0.1-10 mg/ml GST-HABD, GST-3MUT or GST. At the end of the treatment, 10 ml of MTT (Thiozolyl Blue, Sigma) solution (0.5% in PBS) was added to 100 ml of medium in each well. After 3 h incubation with MTT at 371C, the medium was carefully removed and the converted MTT was extracted from cells with acidic isopropanol (0.1 N HCl in isopropanol). Absorbance of converted dye was measured using plate reader at 540 nm with background subtraction at 690 nm.
GST-HABD binding assay
Subconfluent adherent cells were washed once with ice-cold PBS containing 0.1% BSA, 0.1% NaN 3 (stain wash medium, SWM) and removed from plates by scraping. The cells were incubated for 1 h on ice with 5 mg/ml Alexa488 labeled GSTproteins in 100 ml SWM, then washed three times with ice-cold SWM and resuspended in PBS. Fluorescence was analysed by FACSort Flow Cytometer (Becton Dickinson, Franklin Lakes, New Jersey).
Statistical analysis
Statistical analysis of data was perfomed using a heteroscedastic two-tailed Student's t-test.
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